Evidence map›Paper›PMID 31202759›Full record

ReviewJACC. Cardiovascular imaging2020

Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods.

Masaru Obokata, Yogesh N V Reddy, Barry A Borlaug

Open access · greenAbstract readReview
In one paragraph

Review in JACC. Cardiovascular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 289 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Observational
  5. Effects of sympathomodulation on pulse wave properties in heart failure with preserved ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  6. Observational
  7. Chemotherapy-Induced Right Ventricular Dysfunction.Medicina (Kaunas, Lithuania) · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. The Gut-Heart Axis: A Microbiome-Centered Perspective on Heart Failure.International journal of molecular sciences · 2026
    Review
  15. Article
  16. Review
  17. Observational
  18. Review
  19. Article
  20. Review

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Masaru ObokataDepartment of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota.
Yogesh N V ReddyDepartment of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota.
Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota. Electronic address: borlaug.barry@mayo.edu.
Mayo Clinic · US

Funding

Mayo Heart Failure Regional Clinical CenterU10HL110262 · NHLBI · MAYO CLINIC ROCHESTER · PI REDFIELD, MARGARET M · 2012 to 2018
$3.6M
Peripheral Mechanisms of Cardiopulmonary Control during ExerciseR01HL126638 · NHLBI · MAYO CLINIC ROCHESTER · PI OLSON, THOMAS PATRICK · 2015 to 2019
$2.9M
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4M
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).U01HL125205 · NHLBI · MAYO CLINIC ROCHESTER · PI FRANTZ, ROBERT PAUL · 2014 to 2018
$1.5M
NHLBI NIH HHS R01 HL126638NHLBI NIH HHS R01 HL128526NHLBI NIH HHS U01 HL125205NHLBI NIH HHS U10 HL110262
6 · The paper itself

Abstract

Research in the last decade has substantially advanced our understanding of the pathophysiology of heart failure with preserved ejection fraction (HFpEF). However, treatment options remain limited as clinical trials have largely failed to identify effective therapies. Part of this failure may be related to mechanistic heterogeneity. It is speculated that categorizing HFpEF patients based upon underlying pathophysiological phenotypes may represent the key next step in delivering the right therapies to the right patients. Echocardiography may provide valuable insight into both the pathophysiology and underlying phenotypes in HFpEF. Echocardiography also plays a key role in the evaluation of patients with unexplained dyspnea, where HFpEF is suspected but the diagnosis remains unknown. The combination of the E/e' ratio and right ventricular systolic pressure has recently been shown to add independent value to the diagnostic evaluation of patients suspected of having HFpEF. Finally, echocardiography enables identification of the different causes that mimic HFpEF but are treated differently, such as valvular heart disease, pericardial constriction, and high-output heart failure or infiltrative myopathies such as cardiac amyloid. This review summarizes the current understanding of the pathophysiology and phenotyping of HFpEF with particular attention to the role of echocardiography in this context.

Indexed as

EchocardiographyStroke VolumeVentricular Function, LeftComorbidityDiastoleHeart FailureHumansPhenotypePredictive Value of TestsPrognosisRisk FactorsVentricular Dysfunction, Leftdiagnosisdiastolic functionechocardiographyfilling pressureheart failurenoninvasive

Identifiers

PMID31202759
PMCPMC6899218
OpenAlexW2950275058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.